Evidence map›Paper›PMID 42776365›Full record

ArticleAnnals of surgical oncology2026

Real-World Analysis of Neoadjuvant Immunochemotherapy Followed by Surgery in Esophageal Cancer with Baseline Supraclavicular Lymph Node Involvement.

Yimeng Yu, Lin Lin, Ya Zeng, Zhichao Liu, Jingyi Jia, Yunfeng Wang, Yifei Lu, Jingquan Wang, Zhigang Li, Xuwei Cai and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yimeng Yu *Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lin Lin *Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ya ZengDepartment of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhichao LiuDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingyi JiaDepartment of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yunfeng WangDepartment of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yifei LuDepartment of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingquan WangDepartment of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhigang LiDepartment of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhigang.li@shsmu.edu.cn.
Xuwei CaiDepartment of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. birdhome2000@163.com.
Jun LiuDepartment of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. drjunliuplus@163.com.

Funding

Chinese Society of Clinical Oncology Y-2019AZZD-0006Data Center of Management Science, National Natural Science Foundation of China - Peking University 82273575
6 · The paper itself

Abstract

backgroundManagement of supraclavicular lymph node (SCLN) metastasis in esophageal cancer remains controversial. Neoadjuvant immunochemotherapy (nICT) may challenge current staging paradigms. This study evaluated prognosis of esophageal squamous cell carcinoma (ESCC) patients with baseline SCLN metastasis receiving nICT and surgery.

methodsWe retrospectively analyzed 335 ESCC patients (cT1-2N1-3 to T3-4aN0-3 or M1 [limited to SCLN]) receiving nICT and surgery between 2019 and 2021. Patients were stratified into cSCLN+ (n = 110) and cSCLN- (n = 225). Recurrence-free survival (RFS), overall survival (OS), and recurrence patterns were compared. Prognostic factors were assessed by using multivariable Cox regression. The impact of postoperative radiotherapy (PORT) was evaluated within the cSCLN+ subgroup.

resultsPathological response rates were comparable between groups (pCR rates: 20.9% vs. 27.6%, p = 0.238). At a median follow-up of 23.8 months, no significant differences in RFS (p = 0.109) and OS (p = 0.859) were observed, with similar recurrence patterns. Multivariable analysis showed cSCLN status was not an independent prognostic factor. Nevertheless, patients with persistent pathological SCLN positivity (cSCLN+pSCLN+) experienced significantly worse survival (median RFS 12.4 months, median OS 40.4 months; both not reached in other groups). Upper-thoracic tumor and advanced pathological nodal stage were independent risk factors in cSCLN+ cohort. Although PORT did not significantly improve survival in the overall cSCLN+ population, a trend toward improved OS was observed in the cSCLN+pSCLN+ subgroup.

conclusionsEsophageal squamous cell carcinoma patients with clinically positive SCLN might achieve comparable prognosis to those with clinically negative nodes after nICT plus surgery. For patients with residual pathological SCLN positivity, PORT may be considered as a potential strategy to improve survival outcomes.

Indexed as

Esophageal squamous cell carcinomaNeoadjuvant immunochemotherapySupraclavicular lymph node

Identifiers

PMID42776365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.